Comparative Pharmacology
Head-to-head clinical analysis: MOTOFEN versus MYTESI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOTOFEN versus MYTESI.
MOTOFEN vs MYTESI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of diphenoxylate (opioid agonist) and atropine (anticholinergic). Diphenoxylate acts on μ-opioid receptors in the gut to slow peristalsis and reduce fluid secretion; atropine is added to discourage abuse by causing unpleasant anticholinergic effects at high doses.
MYTESI (crofelemer) is a proanthocyanidin oligomer that acts locally in the gastrointestinal tract to inhibit chloride ion secretion by blocking both the cystic fibrosis transmembrane conductance regulator (CFTR) and calcium-activated chloride channels (CaCC) at the luminal surface of enterocytes, thereby reducing fluid and electrolyte secretion.
1 to 2 tablets orally every 6 hours as needed, not to exceed 8 tablets per day.
1 capsule (5 mg) orally three times daily, taken 30 minutes before meals.
None Documented
None Documented
Terminal elimination half-life: 20-24 hours; clinical context: once-daily dosing recommended
1.6 hours (mean terminal elimination half-life); clinical context: short half-life supports oral administration three times daily to maintain therapeutic levels.
Renal: ~60%; Fecal/Biliary: ~40%
Primarily fecal (82-86%) as unchanged drug; renal excretion accounts for <1% of the dose.
Category C
Category C
Antidiarrheal
Antidiarrheal